EOFlow Seeks Approval of Wearable Disposable Insulin Pump for Diabetes in the US
- The company has submitted a 510(k) application to the US FDA for its wearable disposable insulin pump EOPatch that was launched in Korea in Apr 2021, EU in Sept 2022 & UAE’s approval in the same month while in Indonesia in Oct 2022
- The company is currently in talks with the US distributors & plans to sign a distribution agreement in H1’23. EOPatch 3.0 is expected to be available in 2024 & was evaluated in multiple tests with samples that have a 3ml reservoir & can work for 7 days using EOFlow’s pumping technology
- The wearable integrated artificial pancreas solution received BTD in the US which is a wearable disposable device that features a glucose monitoring sensor, an insulin pump & an integrated automated insulin delivery algorithm
Ref: PRNewswire | Image: EOFlow
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.